{"nctId":"NCT00421954","briefTitle":"Open-label Ziprasidone Study for Psychosis Treatment in Adolescents","startDateStruct":{"date":"2006-05"},"conditions":["Schizophreniform Disorder","Schizoaffective Disorder","Psychosis","Depressive Disorder, Major","Bipolar Disorder"],"count":8,"armGroups":[{"label":"Ziprasidone","type":"EXPERIMENTAL","interventionNames":["Drug: Ziprasidone"]}],"interventions":[{"name":"Ziprasidone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Children who meet DSM-IV criteria for the following psychotic disorders: schizophreniform disorder, schizoaffective disorder, psychosis NOS, major depressive disorder with psychotic features, and bipolar disorder with psychotic features.\n2. Children with an IQ of at least 70.\n3. Children who are in good physical health.\n4. The parent/guardian of the child must be willing to attend all study visits.\n\nExclusion Criteria:\n\n1. Children who are currently receiving an effective treatment without detrimental side effects.\n2. Children who are allergic to Geodon®.\n3. Children who have previously failed to respond to an adequate trial of Geodon®.\n4. Females who are pregnant or breast-feeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"13 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Weight Gain and Other Side Effects","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}}